{
    "2018-06-20": [
        [
            {
                "time": "2018-06-20",
                "original_text": "复星医药：子公司逾4亿元收购迪会信28%股权",
                "features": {
                    "keywords": [
                        "复星医药",
                        "收购",
                        "迪会信",
                        "股权"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-20",
                "original_text": "复星医药：顺应供给侧改革，用心做好药",
                "features": {
                    "keywords": [
                        "复星医药",
                        "供给侧改革",
                        "好药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-20",
                "original_text": "国务院常务会确定加快已在境外上市新药审批（股）",
                "features": {
                    "keywords": [
                        "国务院",
                        "新药审批",
                        "政策"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-21",
                "original_text": "21日利好公告：复星医药逾4亿元收购迪会信28%股权(更新中)",
                "features": {
                    "keywords": [
                        "复星医药",
                        "收购",
                        "迪会信",
                        "股权"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-19",
                "original_text": "【金融工程】唐军、潘琨（联系人）：中泰金工事件驱动周报主营产品涨价及冷门股效应-20180619",
                "features": {
                    "keywords": [
                        "金融工程",
                        "主营产品涨价",
                        "冷门股效应"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-20",
                "original_text": "PD-1抗体药物获准进口 国内市场竞争将更趋激烈",
                "features": {
                    "keywords": [
                        "PD-1抗体",
                        "进口",
                        "市场竞争"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-06-20",
                "original_text": "医药周报: 推荐医保目录和一致性评价政策下估值合理、业绩和成长确定表现的",
                "features": {
                    "keywords": [
                        "医保目录",
                        "一致性评价",
                        "政策",
                        "估值合理",
                        "业绩",
                        "成长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}